Molecular Weight:   | 956.11 |
Volume:   | 845.04 |
LogP:   | 1.133 |
LogD:   | 0.669 |
LogS:   | -3.284 |
# Rotatable Bonds:   | 12 |
TPSA:   | 454.16 |
# H-Bond Aceptor:   | 27 |
# H-Bond Donor:   | 14 |
# Rings:   | 7 |
# Heavy Atoms:   | 27 |
QED Drug-Likeness Score:   | 0.042 |
Synthetic Accessibility Score:   | 6.853 |
Fsp3:   | 0.22 |
Lipinski Rule-of-5:   | Rejected |
Pfizer Rule:   | Accepted |
GSK Rule:   | Rejected |
BMS Rule:   | 1 |
Golden Triangle Rule:   | Rejected |
Chelating Alert:   | 2 |
PAINS Alert:   | 1 |
Caco-2 Permeability:   | -7.005 |
MDCK Permeability:   | 8.180858458217699e-06 |
Pgp-inhibitor:   | 0.0 |
Pgp-substrate:   | 0.006 |
Human Intestinal Absorption (HIA):   | 0.977 |
20% Bioavailability (F20%):   | 0.936 |
30% Bioavailability (F30%):   | 1.0 |
Blood-Brain-Barrier Penetration (BBB):   | 0.005 |
Plasma Protein Binding (PPB):   | 81.88787841796875% |
Volume Distribution (VD):   | 0.449 |
Pgp-substrate:   | 39.283226013183594% |
CYP1A2-inhibitor:   | 0.019 |
CYP1A2-substrate:   | 0.006 |
CYP2C19-inhibitor:   | 0.008 |
CYP2C19-substrate:   | 0.014 |
CYP2C9-inhibitor:   | 0.419 |
CYP2C9-substrate:   | 0.027 |
CYP2D6-inhibitor:   | 0.0 |
CYP2D6-substrate:   | 0.044 |
CYP3A4-inhibitor:   | 0.011 |
CYP3A4-substrate:   | 0.0 |
Clearance (CL):   | 8.288 |
Half-life (T1/2):   | 0.989 |
hERG Blockers:   | 0.039 |
Human Hepatotoxicity (H-HT):   | 0.171 |
Drug-inuced Liver Injury (DILI):   | 0.996 |
AMES Toxicity:   | 0.082 |
Rat Oral Acute Toxicity:   | 0.0 |
Maximum Recommended Daily Dose:   | 0.21 |
Skin Sensitization:   | 0.945 |
Carcinogencity:   | 0.038 |
Eye Corrosion:   | 0.003 |
Eye Irritation:   | 0.923 |
Respiratory Toxicity:   | 0.004 |
Natural Product ID:   | NPC7839 |
Common Name*:   | YGVHOSGNOYKRIH-AAYPSMFASA-N |
IUPAC Name:   | n.a. |
Synonyms:   | |
Standard InCHIKey:   | YGVHOSGNOYKRIH-AAYPSMFASA-N |
Standard InCHI:   | InChI=1S/C41H32O27/c42-15-1-10(2-16(43)26(15)51)35(56)62-9-22-31-33(66-36(57)11-3-17(44)27(52)18(45)4-11)34(41(63-22)68-37(58)12-5-19(46)28(53)20(47)6-12)67-38(59)13-7-21(48)29(54)32-25(13)24(30(55)40(61)65-32)14(8-23(49)50)39(60)64-31/h1-7,14,22,24,30-31,33-34,41-48,51-55H,8-9H2,(H,49,50)/t14-,22?,24-,30-,31+,33-,34-,41-/m0/s1 |
SMILES:   | c1c(cc(c(c1O)O)O)C(=O)OCC1[C@@H]2[C@@H]([C@@H]([C@@H](O1)OC(=O)c1cc(c(c(c1)O)O)O)OC(=O)c1cc(c(c3c1[C@H]([C@H](CC(=O)O)C(=O)O2)[C@@H](C(=O)O3)O)O)O)OC(=O)c1cc(c(c(c1)O)O)O |
Synthetic Gene Cluster:   | n.a. |
ChEMBL Identifier:   | CHEMBL1391063 |
PubChem CID:   |
16745534 |
Chemical Classification**:   |
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
Organism ID | Organism Name | Taxonomy Level | Family | SuperKingdom | Isolation Part | Collection Location | Collection Time | Reference |
---|---|---|---|---|---|---|---|---|
NPO26650 | Terminalia chebula | Species | Combretaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[11520216] |
NPO28450 | Phyllanthus emblica | Species | Phyllanthaceae | Eukaryota | n.a. | n.a. | n.a. |
PMID[11754604] |
NPO28450 | Phyllanthus emblica | Species | Phyllanthaceae | Eukaryota | Roots | Simao city, Yunnan Province, China | 2007-MAY |
PMID[19374435] |
NPO26650 | Terminalia chebula | Species | Combretaceae | Eukaryota | n.a. | n.a. | n.a. | Database[HerDing] |
NPO28450 | Phyllanthus emblica | Species | Phyllanthaceae | Eukaryota | n.a. | n.a. | n.a. | Database[HerDing] |
NPO11632 | Fructus phyllanthi | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Database[HerDing] |
NPO3942 | Geranium pratense | Species | Geraniaceae | Eukaryota | n.a. | n.a. | n.a. | Database[HerDing] |
NPO3942 | Geranium pratense | Species | Geraniaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCMID] |
NPO11632 | Fructus phyllanthi | n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | Database[TCMID] |
NPO28450 | Phyllanthus emblica | Species | Phyllanthaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCMID] |
NPO26650 | Terminalia chebula | Species | Combretaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCMID] |
NPO28450 | Phyllanthus emblica | Species | Phyllanthaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCM_Taiwan] |
NPO3942 | Geranium pratense | Species | Geraniaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCM_Taiwan] |
NPO26650 | Terminalia chebula | Species | Combretaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TCM_Taiwan] |
NPO28450 | Phyllanthus emblica | Species | Phyllanthaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TM-MC] |
NPO22244 | Terminalia bellirica | Species | Combretaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TM-MC] |
NPO26650 | Terminalia chebula | Species | Combretaceae | Eukaryota | n.a. | n.a. | n.a. | Database[TM-MC] |
NPO26650 | Terminalia chebula | Species | Combretaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO3942 | Geranium pratense | Species | Geraniaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
NPO28450 | Phyllanthus emblica | Species | Phyllanthaceae | Eukaryota | n.a. | n.a. | n.a. | Database[UNPD] |
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Organism ID | NP ID | Organism Material Preparation | Organism Part | NP Quantity (Standard) | NP Quantity (Minimum) | NP Quantity (Maximum) | Quantity Unit | Reference |
---|
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
Target ID | Target Type | Target Name | Target Organism | Activity Type | Activity Relation | Value | Unit | Reference |
---|---|---|---|---|---|---|---|---|
NPT44 | Individual Protein | Bifunctional protein glmU | Mycobacterium tuberculosis | IC50 | > | 9999000.0 | nM | PMID[476430] |
NPT45 | Individual Protein | Ubiquitin carboxyl-terminal hydrolase 2 | Homo sapiens | Potency | = | 891.3 | nM | PMID[476430] |
NPT47 | Individual Protein | ATP-dependent DNA helicase Q1 | Homo sapiens | Potency | = | 112.2 | nM | PMID[476430] |
NPT48 | Individual Protein | Lysine-specific demethylase 4D-like | Homo sapiens | Potency | = | 707.9 | nM | PMID[476430] |
NPT1038 | Individual Protein | Histone-lysine N-methyltransferase MLL | Homo sapiens | Potency | = | 28183.8 | nM | PMID[476430] |
NPT49 | Individual Protein | DNA-(apurinic or apyrimidinic site) lyase | Homo sapiens | Potency | = | 2.2 | nM | PMID[476430] |
NPT50 | Individual Protein | Tyrosyl-DNA phosphodiesterase 1 | Homo sapiens | Potency | = | 31.6 | nM | PMID[476430] |
NPT51 | Individual Protein | Microtubule-associated protein tau | Homo sapiens | Potency | = | 15848.9 | nM | PMID[476430] |
NPT46 | Individual Protein | Thyroid hormone receptor beta-1 | Homo sapiens | Potency | = | 44668.4 | nM | PMID[476430] |
NPT52 | Individual Protein | Pyruvate kinase isozymes M1/M2 | Homo sapiens | Potency | = | 112.2 | nM | PMID[476430] |
NPT3 | Individual Protein | Thioredoxin glutathione reductase | Schistosoma mansoni | Potency | = | 15848.9 | nM | PMID[476430] |
NPT53 | Individual Protein | 4'-phosphopantetheinyl transferase ffp | Bacillus subtilis | Potency | = | 44668.4 | nM | PMID[476430] |
NPT60 | Individual Protein | Lysosomal alpha-glucosidase | Homo sapiens | Potency | = | 39810.7 | nM | PMID[476430] |
NPT55 | Individual Protein | Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | = | 3971.6 | nM | PMID[476430] |
NPT282 | Individual Protein | MAP kinase ERK2 | Homo sapiens | Potency | = | 39810.7 | nM | PMID[476430] |
NPT57 | Individual Protein | Induced myeloid leukemia cell differentiation protein Mcl-1 | Homo sapiens | IC50 | = | 1522.67 | nM | PMID[476430] |
NPT60 | Individual Protein | Lysosomal alpha-glucosidase | Homo sapiens | Potency | = | 1572.8 | nM | PMID[476430] |
NPT58 | Individual Protein | Bloom syndrome protein | Homo sapiens | Potency | = | 100.0 | nM | PMID[476430] |
NPT59 | Individual Protein | DNA polymerase beta | Homo sapiens | Potency | = | 177.8 | nM | PMID[476430] |
NPT47 | Individual Protein | ATP-dependent DNA helicase Q1 | Homo sapiens | Potency | = | 446.7 | nM | PMID[476430] |
NPT62 | Individual Protein | 6-phospho-1-fructokinase | Trypanosoma brucei | Potency | n.a. | 1510.1 | nM | PMID[476430] |
NPT1039 | Individual Protein | Envelope glycoprotein gp160 | Human immunodeficiency virus 1 | IC50 | = | 11200.0 | nM | PMID[476430] |
NPT63 | Individual Protein | Bromodomain adjacent to zinc finger domain protein 2B | Homo sapiens | Potency | n.a. | 707.9 | nM | PMID[476430] |
NPT484 | Individual Protein | Luciferin 4-monooxygenase | Photinus pyralis | Potency | n.a. | 26854.5 | nM | PMID[476430] |
NPT105 | Individual Protein | Muscleblind-like protein 1 | Homo sapiens | Potency | n.a. | 100.0 | nM | PMID[476430] |
NPT49 | Individual Protein | DNA-(apurinic or apyrimidinic site) lyase | Homo sapiens | Potency | n.a. | 8.9 | nM | PMID[476430] |
NPT1040 | Individual Protein | Human immunodeficiency virus type 1 Tat protein | Human immunodeficiency virus type 1 group M subtype B (isolate HXB2)(HIV-1) | IC50 | n.a. | 556.0 | nM | PMID[476430] |
NPT2 | Others | Unspecified | Potency | = | 31622.8 | nM | PMID[476430] | |
NPT2 | Others | Unspecified | Potency | = | 398.1 | nM | PMID[476430] | |
NPT312 | Organism | Saccharomyces cerevisiae | Saccharomyces cerevisiae | Potency | = | 35481.3 | nM | PMID[476430] |
NPT533 | Protein-Protein Interaction | Runt-related transcription factor 1/Core-binding factor subunit beta | Homo sapiens | Potency | n.a. | 31.6 | nM | PMID[476430] |
NPT2 | Others | Unspecified | Potency | n.a. | 19952.6 | nM | PMID[476430] | |
NPT533 | Protein-Protein Interaction | Runt-related transcription factor 1/Core-binding factor subunit beta | Homo sapiens | Potency | n.a. | 31622.8 | nM | PMID[476430] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 2936.2 | nM | PMID[476430] |
NPT6 | Organism | Plasmodium falciparum | Plasmodium falciparum | Potency | n.a. | 3294.4 | nM | PMID[476430] |
NPT533 | Protein-Protein Interaction | Runt-related transcription factor 1/Core-binding factor subunit beta | Homo sapiens | Potency | n.a. | 89.1 | nM | PMID[476430] |
NPT20529 | NON-MOLECULAR | NON-PROTEIN TARGET | n.a. | CC50 | > | 40000.0 | nM | PMID[476430] |
NPT2 | Others | Unspecified | IC50 | < | 195.0 | nM | PMID[476430] |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC7839 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Natural Product ID |
---|---|---|
1.0 | High Similarity | NPC142291 |
0.9884 | High Similarity | NPC119094 |
0.9884 | High Similarity | NPC173872 |
0.9535 | High Similarity | NPC80956 |
0.9419 | High Similarity | NPC297574 |
0.9379 | High Similarity | NPC201814 |
0.9314 | High Similarity | NPC129533 |
0.9314 | High Similarity | NPC123259 |
0.9306 | High Similarity | NPC472723 |
0.927 | High Similarity | NPC472721 |
0.927 | High Similarity | NPC472720 |
0.927 | High Similarity | NPC31208 |
0.927 | High Similarity | NPC160543 |
0.927 | High Similarity | NPC93065 |
0.927 | High Similarity | NPC469652 |
0.927 | High Similarity | NPC472724 |
0.9227 | High Similarity | NPC3474 |
0.9213 | High Similarity | NPC477081 |
0.9213 | High Similarity | NPC269046 |
0.9213 | High Similarity | NPC477083 |
0.9213 | High Similarity | NPC240200 |
0.9213 | High Similarity | NPC158214 |
0.9213 | High Similarity | NPC223534 |
0.9213 | High Similarity | NPC290289 |
0.9209 | High Similarity | NPC111490 |
0.9209 | High Similarity | NPC261623 |
0.9195 | High Similarity | NPC473713 |
0.9162 | High Similarity | NPC187632 |
0.9157 | High Similarity | NPC65489 |
0.9157 | High Similarity | NPC237202 |
0.9157 | High Similarity | NPC469649 |
0.9157 | High Similarity | NPC260521 |
0.9153 | High Similarity | NPC231254 |
0.9148 | High Similarity | NPC8940 |
0.9128 | High Similarity | NPC149300 |
0.9116 | High Similarity | NPC477082 |
0.9116 | High Similarity | NPC476358 |
0.9111 | High Similarity | NPC97924 |
0.9111 | High Similarity | NPC264302 |
0.9111 | High Similarity | NPC40078 |
0.9111 | High Similarity | NPC471091 |
0.9101 | High Similarity | NPC469650 |
0.908 | High Similarity | NPC166674 |
0.908 | High Similarity | NPC46640 |
0.908 | High Similarity | NPC34436 |
0.908 | High Similarity | NPC263119 |
0.908 | High Similarity | NPC219600 |
0.908 | High Similarity | NPC473550 |
0.9075 | High Similarity | NPC181778 |
0.9075 | High Similarity | NPC470272 |
0.907 | High Similarity | NPC311389 |
0.907 | High Similarity | NPC470271 |
0.907 | High Similarity | NPC473818 |
0.904 | High Similarity | NPC170203 |
0.904 | High Similarity | NPC208797 |
0.904 | High Similarity | NPC53680 |
0.9023 | High Similarity | NPC100251 |
0.9023 | High Similarity | NPC65333 |
0.9017 | High Similarity | NPC658 |
0.9017 | High Similarity | NPC197708 |
0.9016 | High Similarity | NPC189312 |
0.9012 | High Similarity | NPC175793 |
0.8994 | High Similarity | NPC104910 |
0.8994 | High Similarity | NPC474093 |
0.8989 | High Similarity | NPC470718 |
0.8989 | High Similarity | NPC297503 |
0.8989 | High Similarity | NPC97119 |
0.8989 | High Similarity | NPC135831 |
0.8983 | High Similarity | NPC198902 |
0.8977 | High Similarity | NPC67629 |
0.8977 | High Similarity | NPC79736 |
0.8973 | High Similarity | NPC470450 |
0.8971 | High Similarity | NPC98583 |
0.896 | High Similarity | NPC261411 |
0.896 | High Similarity | NPC190204 |
0.896 | High Similarity | NPC43918 |
0.8944 | High Similarity | NPC475360 |
0.8944 | High Similarity | NPC72554 |
0.8944 | High Similarity | NPC30011 |
0.8944 | High Similarity | NPC97817 |
0.8944 | High Similarity | NPC475179 |
0.8939 | High Similarity | NPC25946 |
0.8939 | High Similarity | NPC470720 |
0.8939 | High Similarity | NPC470713 |
0.8939 | High Similarity | NPC21359 |
0.8939 | High Similarity | NPC460984 |
0.8939 | High Similarity | NPC470717 |
0.8933 | High Similarity | NPC125352 |
0.8927 | High Similarity | NPC267549 |
0.892 | High Similarity | NPC473630 |
0.8914 | High Similarity | NPC5786 |
0.8914 | High Similarity | NPC102851 |
0.8908 | High Similarity | NPC198125 |
0.8908 | High Similarity | NPC95421 |
0.8895 | High Similarity | NPC121290 |
0.8889 | High Similarity | NPC473554 |
0.8889 | High Similarity | NPC295625 |
0.8889 | High Similarity | NPC470719 |
0.8889 | High Similarity | NPC112380 |
0.8883 | High Similarity | NPC162394 |
0.8883 | High Similarity | NPC241781 |
0.8883 | High Similarity | NPC156785 |
0.8883 | High Similarity | NPC132111 |
0.8876 | High Similarity | NPC471030 |
0.8864 | High Similarity | NPC163165 |
0.8857 | High Similarity | NPC47521 |
0.8851 | High Similarity | NPC31034 |
0.884 | High Similarity | NPC105591 |
0.884 | High Similarity | NPC269625 |
0.8837 | High Similarity | NPC291957 |
0.8837 | High Similarity | NPC14030 |
0.8833 | High Similarity | NPC223860 |
0.8833 | High Similarity | NPC275977 |
0.8833 | High Similarity | NPC249560 |
0.8833 | High Similarity | NPC318119 |
0.8827 | High Similarity | NPC117668 |
0.8827 | High Similarity | NPC469371 |
0.882 | High Similarity | NPC113836 |
0.882 | High Similarity | NPC476620 |
0.882 | High Similarity | NPC37668 |
0.882 | High Similarity | NPC476622 |
0.882 | High Similarity | NPC293626 |
0.882 | High Similarity | NPC476618 |
0.882 | High Similarity | NPC476623 |
0.882 | High Similarity | NPC476619 |
0.882 | High Similarity | NPC253521 |
0.882 | High Similarity | NPC258044 |
0.882 | High Similarity | NPC267680 |
0.882 | High Similarity | NPC217387 |
0.882 | High Similarity | NPC196127 |
0.882 | High Similarity | NPC476621 |
0.8817 | High Similarity | NPC174140 |
0.8807 | High Similarity | NPC47140 |
0.8807 | High Similarity | NPC38438 |
0.8807 | High Similarity | NPC67134 |
0.8786 | High Similarity | NPC470898 |
0.8785 | High Similarity | NPC221140 |
0.8785 | High Similarity | NPC473686 |
0.8785 | High Similarity | NPC33083 |
0.8785 | High Similarity | NPC475352 |
0.8785 | High Similarity | NPC475220 |
0.8785 | High Similarity | NPC229817 |
0.8778 | High Similarity | NPC321916 |
0.8771 | High Similarity | NPC472726 |
0.8771 | High Similarity | NPC472725 |
0.8764 | High Similarity | NPC144097 |
0.8764 | High Similarity | NPC61904 |
0.8757 | High Similarity | NPC175230 |
0.8757 | High Similarity | NPC88560 |
0.8757 | High Similarity | NPC316539 |
0.8757 | High Similarity | NPC172033 |
0.875 | High Similarity | NPC204937 |
0.875 | High Similarity | NPC149011 |
0.8743 | High Similarity | NPC249977 |
0.8736 | High Similarity | NPC179947 |
0.8736 | High Similarity | NPC64755 |
0.8729 | High Similarity | NPC470451 |
0.8729 | High Similarity | NPC470416 |
0.8729 | High Similarity | NPC470455 |
0.8728 | High Similarity | NPC476371 |
0.8728 | High Similarity | NPC285108 |
0.8728 | High Similarity | NPC33298 |
0.8728 | High Similarity | NPC476372 |
0.8721 | High Similarity | NPC289346 |
0.8721 | High Similarity | NPC24627 |
0.8721 | High Similarity | NPC24164 |
0.8715 | High Similarity | NPC477895 |
0.8715 | High Similarity | NPC217520 |
0.8715 | High Similarity | NPC35167 |
0.8715 | High Similarity | NPC472387 |
0.8715 | High Similarity | NPC139571 |
0.8715 | High Similarity | NPC173837 |
0.8713 | High Similarity | NPC238419 |
0.8713 | High Similarity | NPC172419 |
0.8708 | High Similarity | NPC34267 |
0.8708 | High Similarity | NPC81042 |
0.8708 | High Similarity | NPC253685 |
0.8708 | High Similarity | NPC214621 |
0.8708 | High Similarity | NPC171706 |
0.8708 | High Similarity | NPC223426 |
0.8689 | High Similarity | NPC205721 |
0.8689 | High Similarity | NPC473618 |
0.8681 | High Similarity | NPC87583 |
0.8678 | High Similarity | NPC227297 |
0.8674 | High Similarity | NPC473717 |
0.8674 | High Similarity | NPC473631 |
0.8674 | High Similarity | NPC199172 |
0.8674 | High Similarity | NPC470445 |
0.8674 | High Similarity | NPC470446 |
0.8674 | High Similarity | NPC470447 |
0.8674 | High Similarity | NPC470449 |
0.8674 | High Similarity | NPC36138 |
0.8674 | High Similarity | NPC35924 |
0.8674 | High Similarity | NPC293227 |
0.8674 | High Similarity | NPC475662 |
0.8667 | High Similarity | NPC212290 |
0.8663 | High Similarity | NPC104222 |
0.8663 | High Similarity | NPC87317 |
0.8663 | High Similarity | NPC114791 |
0.8663 | High Similarity | NPC210501 |
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC7839 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
Similarity Score | Similarity Level | Drug ID | Developmental Stage |
---|---|---|---|
0.9023 | High Similarity | NPD7993 | Clinical (unspecified phase) |
0.8655 | High Similarity | NPD4868 | Clinical (unspecified phase) |
0.8603 | High Similarity | NPD7808 | Phase 3 |
0.8547 | High Similarity | NPD7251 | Discontinued |
0.8539 | High Similarity | NPD7472 | Approved |
0.8539 | High Similarity | NPD7074 | Phase 3 |
0.85 | High Similarity | NPD4338 | Clinical (unspecified phase) |
0.8492 | Intermediate Similarity | NPD6797 | Phase 2 |
0.8483 | Intermediate Similarity | NPD7054 | Approved |
0.8453 | Intermediate Similarity | NPD8313 | Approved |
0.8453 | Intermediate Similarity | NPD8312 | Approved |
0.843 | Intermediate Similarity | NPD1465 | Phase 2 |
0.8427 | Intermediate Similarity | NPD7228 | Approved |
0.8418 | Intermediate Similarity | NPD6168 | Clinical (unspecified phase) |
0.8418 | Intermediate Similarity | NPD6166 | Phase 2 |
0.8418 | Intermediate Similarity | NPD6167 | Clinical (unspecified phase) |
0.8324 | Intermediate Similarity | NPD3818 | Discontinued |
0.8278 | Intermediate Similarity | NPD5844 | Phase 1 |
0.8235 | Intermediate Similarity | NPD7879 | Clinical (unspecified phase) |
0.8177 | Intermediate Similarity | NPD7804 | Clinical (unspecified phase) |
0.8128 | Intermediate Similarity | NPD8397 | Clinical (unspecified phase) |
0.8114 | Intermediate Similarity | NPD8455 | Phase 2 |
0.8079 | Intermediate Similarity | NPD4381 | Clinical (unspecified phase) |
0.8071 | Intermediate Similarity | NPD8151 | Discontinued |
0.8065 | Intermediate Similarity | NPD8055 | Clinical (unspecified phase) |
0.8056 | Intermediate Similarity | NPD7184 | Clinical (unspecified phase) |
0.8045 | Intermediate Similarity | NPD7199 | Phase 2 |
0.8043 | Intermediate Similarity | NPD7240 | Approved |
0.8034 | Intermediate Similarity | NPD6234 | Discontinued |
0.7967 | Intermediate Similarity | NPD7473 | Discontinued |
0.7955 | Intermediate Similarity | NPD37 | Approved |
0.7946 | Intermediate Similarity | NPD7685 | Pre-registration |
0.7921 | Intermediate Similarity | NPD4966 | Approved |
0.7921 | Intermediate Similarity | NPD4965 | Approved |
0.7921 | Intermediate Similarity | NPD4967 | Phase 2 |
0.7901 | Intermediate Similarity | NPD6232 | Discontinued |
0.7853 | Intermediate Similarity | NPD1934 | Approved |
0.7845 | Intermediate Similarity | NPD6959 | Discontinued |
0.7829 | Intermediate Similarity | NPD1653 | Approved |
0.7826 | Intermediate Similarity | NPD3751 | Discontinued |
0.7778 | Intermediate Similarity | NPD7075 | Discontinued |
0.7765 | Intermediate Similarity | NPD3817 | Phase 2 |
0.7727 | Intermediate Similarity | NPD7435 | Discontinued |
0.7722 | Intermediate Similarity | NPD3882 | Suspended |
0.7717 | Intermediate Similarity | NPD7852 | Clinical (unspecified phase) |
0.7709 | Intermediate Similarity | NPD7819 | Suspended |
0.7709 | Intermediate Similarity | NPD2393 | Clinical (unspecified phase) |
0.7705 | Intermediate Similarity | NPD3787 | Discontinued |
0.767 | Intermediate Similarity | NPD6980 | Clinical (unspecified phase) |
0.7667 | Intermediate Similarity | NPD8443 | Clinical (unspecified phase) |
0.766 | Intermediate Similarity | NPD6559 | Discontinued |
0.7638 | Intermediate Similarity | NPD7697 | Approved |
0.7638 | Intermediate Similarity | NPD7696 | Phase 3 |
0.7638 | Intermediate Similarity | NPD7680 | Approved |
0.7638 | Intermediate Similarity | NPD7698 | Approved |
0.7635 | Intermediate Similarity | NPD7783 | Phase 2 |
0.7635 | Intermediate Similarity | NPD7782 | Clinical (unspecified phase) |
0.7614 | Intermediate Similarity | NPD7237 | Clinical (unspecified phase) |
0.7611 | Intermediate Similarity | NPD2801 | Approved |
0.7611 | Intermediate Similarity | NPD7096 | Clinical (unspecified phase) |
0.76 | Intermediate Similarity | NPD7870 | Phase 2 |
0.76 | Intermediate Similarity | NPD8320 | Phase 1 |
0.76 | Intermediate Similarity | NPD8319 | Approved |
0.76 | Intermediate Similarity | NPD7871 | Phase 2 |
0.7596 | Intermediate Similarity | NPD5494 | Approved |
0.7586 | Intermediate Similarity | NPD7875 | Clinical (unspecified phase) |
0.7586 | Intermediate Similarity | NPD7874 | Approved |
0.7582 | Intermediate Similarity | NPD3749 | Approved |
0.7576 | Intermediate Similarity | NPD6779 | Approved |
0.7576 | Intermediate Similarity | NPD6781 | Approved |
0.7576 | Intermediate Similarity | NPD6778 | Approved |
0.7576 | Intermediate Similarity | NPD6782 | Approved |
0.7576 | Intermediate Similarity | NPD6777 | Approved |
0.7576 | Intermediate Similarity | NPD6780 | Approved |
0.7576 | Intermediate Similarity | NPD6776 | Approved |
0.7574 | Intermediate Similarity | NPD7701 | Phase 2 |
0.7569 | Intermediate Similarity | NPD5402 | Approved |
0.7542 | Intermediate Similarity | NPD4380 | Phase 2 |
0.7527 | Intermediate Similarity | NPD7768 | Phase 2 |
0.7514 | Intermediate Similarity | NPD1512 | Approved |
0.75 | Intermediate Similarity | NPD7411 | Suspended |
0.7486 | Intermediate Similarity | NPD6190 | Approved |
0.7475 | Intermediate Similarity | NPD7700 | Phase 2 |
0.7475 | Intermediate Similarity | NPD7699 | Phase 2 |
0.7463 | Intermediate Similarity | NPD7801 | Approved |
0.7461 | Intermediate Similarity | NPD8434 | Phase 2 |
0.7459 | Intermediate Similarity | NPD6801 | Discontinued |
0.7457 | Intermediate Similarity | NPD7266 | Discontinued |
0.7429 | Intermediate Similarity | NPD3750 | Approved |
0.7401 | Intermediate Similarity | NPD1511 | Approved |
0.7401 | Intermediate Similarity | NPD6143 | Clinical (unspecified phase) |
0.7374 | Intermediate Similarity | NPD5403 | Approved |
0.7371 | Intermediate Similarity | NPD8150 | Discontinued |
0.7366 | Intermediate Similarity | NPD8127 | Discontinued |
0.7323 | Intermediate Similarity | NPD6534 | Approved |
0.7323 | Intermediate Similarity | NPD6535 | Approved |
0.7311 | Intermediate Similarity | NPD8155 | Clinical (unspecified phase) |
0.7303 | Intermediate Similarity | NPD6799 | Approved |
0.7293 | Intermediate Similarity | NPD5808 | Clinical (unspecified phase) |
0.7293 | Intermediate Similarity | NPD7458 | Discontinued |
0.7273 | Intermediate Similarity | NPD6674 | Discontinued |
0.7267 | Intermediate Similarity | NPD230 | Phase 1 |
0.7263 | Intermediate Similarity | NPD7004 | Clinical (unspecified phase) |
0.7263 | Intermediate Similarity | NPD5401 | Approved |
0.7253 | Intermediate Similarity | NPD6599 | Discontinued |
0.7232 | Intermediate Similarity | NPD4628 | Phase 3 |
0.7216 | Intermediate Similarity | NPD970 | Clinical (unspecified phase) |
0.7216 | Intermediate Similarity | NPD1549 | Phase 2 |
0.7209 | Intermediate Similarity | NPD1612 | Clinical (unspecified phase) |
0.7209 | Intermediate Similarity | NPD1613 | Approved |
0.7198 | Intermediate Similarity | NPD3226 | Approved |
0.7196 | Intermediate Similarity | NPD3926 | Phase 2 |
0.7179 | Intermediate Similarity | NPD7090 | Clinical (unspecified phase) |
0.7175 | Intermediate Similarity | NPD7421 | Clinical (unspecified phase) |
0.7167 | Intermediate Similarity | NPD4378 | Clinical (unspecified phase) |
0.7159 | Intermediate Similarity | NPD1552 | Clinical (unspecified phase) |
0.7159 | Intermediate Similarity | NPD1550 | Clinical (unspecified phase) |
0.7157 | Intermediate Similarity | NPD6823 | Phase 2 |
0.7143 | Intermediate Similarity | NPD3748 | Approved |
0.7083 | Intermediate Similarity | NPD5619 | Clinical (unspecified phase) |
0.7079 | Intermediate Similarity | NPD8090 | Clinical (unspecified phase) |
0.7074 | Intermediate Similarity | NPD919 | Approved |
0.7072 | Intermediate Similarity | NPD2534 | Approved |
0.7072 | Intermediate Similarity | NPD2533 | Approved |
0.7072 | Intermediate Similarity | NPD7410 | Clinical (unspecified phase) |
0.7072 | Intermediate Similarity | NPD2532 | Approved |
0.7067 | Intermediate Similarity | NPD7585 | Approved |
0.7053 | Intermediate Similarity | NPD7229 | Phase 3 |
0.7039 | Intermediate Similarity | NPD6398 | Clinical (unspecified phase) |
0.7033 | Intermediate Similarity | NPD6273 | Approved |
0.7019 | Intermediate Similarity | NPD7583 | Approved |
0.7018 | Intermediate Similarity | NPD1530 | Clinical (unspecified phase) |
0.7005 | Intermediate Similarity | NPD5353 | Approved |
0.6994 | Remote Similarity | NPD6859 | Clinical (unspecified phase) |
0.699 | Remote Similarity | NPD7549 | Discontinued |
0.6989 | Remote Similarity | NPD7097 | Phase 1 |
0.6978 | Remote Similarity | NPD7422 | Clinical (unspecified phase) |
0.6977 | Remote Similarity | NPD1529 | Clinical (unspecified phase) |
0.6976 | Remote Similarity | NPD7501 | Clinical (unspecified phase) |
0.6949 | Remote Similarity | NPD1510 | Phase 2 |
0.6944 | Remote Similarity | NPD8166 | Discontinued |
0.6944 | Remote Similarity | NPD1878 | Clinical (unspecified phase) |
0.6936 | Remote Similarity | NPD3027 | Phase 3 |
0.6931 | Remote Similarity | NPD6214 | Clinical (unspecified phase) |
0.6931 | Remote Similarity | NPD6213 | Phase 3 |
0.6931 | Remote Similarity | NPD6212 | Phase 3 |
0.6923 | Remote Similarity | NPD7390 | Discontinued |
0.6911 | Remote Similarity | NPD1247 | Approved |
0.691 | Remote Similarity | NPD2796 | Approved |
0.691 | Remote Similarity | NPD6100 | Approved |
0.691 | Remote Similarity | NPD6099 | Approved |
0.6897 | Remote Similarity | NPD6798 | Discontinued |
0.6879 | Remote Similarity | NPD4908 | Phase 1 |
0.6875 | Remote Similarity | NPD447 | Suspended |
0.6875 | Remote Similarity | NPD1933 | Approved |
0.6875 | Remote Similarity | NPD6355 | Discontinued |
0.6857 | Remote Similarity | NPD7584 | Approved |
0.6854 | Remote Similarity | NPD651 | Clinical (unspecified phase) |
0.6851 | Remote Similarity | NPD7003 | Approved |
0.6839 | Remote Similarity | NPD5242 | Approved |
0.6821 | Remote Similarity | NPD7177 | Discontinued |
0.6818 | Remote Similarity | NPD943 | Approved |
0.6818 | Remote Similarity | NPD4060 | Phase 1 |
0.6816 | Remote Similarity | NPD6841 | Approved |
0.6816 | Remote Similarity | NPD6843 | Phase 3 |
0.6816 | Remote Similarity | NPD1551 | Phase 2 |
0.6816 | Remote Similarity | NPD6842 | Approved |
0.681 | Remote Similarity | NPD7211 | Clinical (unspecified phase) |
0.68 | Remote Similarity | NPD3764 | Approved |
0.68 | Remote Similarity | NPD4907 | Clinical (unspecified phase) |
0.6791 | Remote Similarity | NPD7930 | Approved |
0.6782 | Remote Similarity | NPD4287 | Approved |
0.678 | Remote Similarity | NPD7667 | Clinical (unspecified phase) |
0.6768 | Remote Similarity | NPD7039 | Approved |
0.6768 | Remote Similarity | NPD7038 | Approved |
0.6763 | Remote Similarity | NPD8285 | Discontinued |
0.6761 | Remote Similarity | NPD6233 | Phase 2 |
0.6757 | Remote Similarity | NPD8058 | Clinical (unspecified phase) |
0.6757 | Remote Similarity | NPD8059 | Phase 3 |
0.6755 | Remote Similarity | NPD7615 | Clinical (unspecified phase) |
0.675 | Remote Similarity | NPD8053 | Approved |
0.675 | Remote Similarity | NPD8054 | Approved |
0.6737 | Remote Similarity | NPD4288 | Approved |
0.6725 | Remote Similarity | NPD9269 | Phase 2 |
0.6723 | Remote Similarity | NPD1240 | Approved |
0.6722 | Remote Similarity | NPD5404 | Approved |
0.6722 | Remote Similarity | NPD5405 | Approved |
0.6722 | Remote Similarity | NPD2935 | Discontinued |
0.6722 | Remote Similarity | NPD5406 | Approved |
0.6722 | Remote Similarity | NPD5408 | Approved |
0.6717 | Remote Similarity | NPD5953 | Discontinued |
0.6705 | Remote Similarity | NPD3268 | Approved |
0.6701 | Remote Similarity | NPD5710 | Approved |
0.6701 | Remote Similarity | NPD5711 | Approved |
0.6685 | Remote Similarity | NPD5124 | Phase 1 |
0.6685 | Remote Similarity | NPD2346 | Discontinued |
0.6685 | Remote Similarity | NPD5123 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD6385 | Approved |
0.6667 | Remote Similarity | NPD1509 | Clinical (unspecified phase) |
0.6667 | Remote Similarity | NPD5005 | Approved |
Bioactivity similarity was calculated based on bioactivity descriptors of compounds. The bioactivity descriptors were calculated by a recently developed AI algorithm Chemical Checker (CC) [Nature Biotechnology, 38:1087–1096, 2020; Nature Communications, 12:3932, 2021], which evaluated bioactivity similarities at five levels:
☉ A: chemistry similarity;
☉ B: biological targets similarity;
☉ C: networks similarity;
☉ D: cell-based bioactivity similarity;
☉ E: similarity based on clinical data.
Those 5 categories of CC bioactivity descriptors were calculated and then subjected to manifold projection using UMAP algorithm, to project all NPs on a 2-Dimensional space. The current NP was highlighted with a small circle in the 2-D map. Below figures: left-to-right, A-to-E.